Antinuclear Antibodies (ANA) in Gordon Setters with Symmetrical Lupoid Onychodystrophy and Black Hair Follicular Dysplasia

Bohnhorst, Janne Ø.; Hanssen, I; Moen, Torolf

doi:10.1186/1751-0147-42-323

Cited by 14 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially, separation of claw from claw bed and subsequent sloughing is noted on one or more claws, but within two to three months all claws might be affected. Re-growth results in dystrophic claws, brittle, crumbling and misshapen claws [2] . A thorough clinical investigation is important for a correct diagnosis [3] .…”

Section: Introductionmentioning

confidence: 99%

“…In dogs, SLO is a significant health concern and appears to be the most common immune-mediated claw disease [4] . Particularly high disease prevalence has been reported in certain breeds such as Gordon setters (12.6%) [13] , [2] . English setters, giant schnauzers (10%) and also bearded collies are reported to have a high incidence of SLO (unpublished observation).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

DLA Class II Alleles Are Associated with Risk for Canine Symmetrical Lupoid Onychodystropy (SLO)

et al. 2010

View full text Add to dashboard Cite

Symmetrical lupoid onychodystrophy (SLO) is an immune-mediated disease in dogs affecting the claws with a suggested autoimmune aethiology. Sequence-based genotyping of the polymorphic exon 2 from DLA-DRB1, -DQA1, and -DQB1 class II loci were performed in a total of 98 SLO Gordon setter cases and 98 healthy controls. A risk haplotype (DRB1*01801/DQA1*00101/DQB1*00802) was present in 53% of cases and 34% of controls and conferred an elevated risk of developing SLO with an odds ratio (OR) of 2.1. When dogs homozygous for the risk haplotype were compared to all dogs not carrying the haplotype the OR was 5.4. However, a stronger protective haplotype (DRB1*02001/DQA1*00401/DQB1*01303, OR = 0.03, 1/OR = 33) was present in 16.8% of controls, but only in a single case (0.5%). The effect of the protective haplotype was clearly stronger than the risk haplotype, since 11.2% of the controls were heterozygous for the risk and protective haplotypes, whereas this combination was absent from cases. When the dogs with the protective haplotype were excluded, an OR of 2.5 was obtained when dogs homozygous for the risk haplotype were compared to those heterozygous for the risk haplotype, suggesting a co-dominant effect of the risk haplotype. In smaller sample sizes of the bearded collie and giant schnauzer breeds we found the same or similar haplotypes, sharing the same DQA1 allele, over-represented among the cases suggesting that the risk is associated primarily with DLA-DQ. We obtained conclusive results that DLA class II is significantly associated with risk of developing SLO in Gordon setters, thus supporting that SLO is an immune-mediated disease. Further studies of SLO in dogs may provide important insight into immune privilege of the nail apparatus and also knowledge about a number of inflammatory disorders of the nail apparatus like lichen planus, psoriasis, alopecia areata and onycholysis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

DLA Class II Alleles Are Associated with Risk for Canine Symmetrical Lupoid Onychodystropy (SLO)

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Small studies included <30 cases in any analysis cohort; medium, 30 to 99 cases in any analysis cohort; and large ≥100 cases in any analysis cohort. Most biomarker studies analyzed small case cohorts (24/49), 65 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 18 studies were midsized, 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 and 7 were large. 66 , 108 , 109 , 110 , 111 , 112 …”

Section: Resultsmentioning

confidence: 99%

“…Other studies created cohorts based on the presence or absence of comorbidities. 79 , 86 A few studies cited data from smaller nested pilot studies in addition to reporting the findings of their larger study. 108 , 113 …”

Section: Resultsmentioning

confidence: 99%

“…Numbers of enrolled controls varied from 1 74 , 75 to 1057. 101 Most studies (31/49) used ≤30 controls in analysis cohorts 65 , 66 , 67 , 69 , 70 , 71 , 72 , 74 , 75 , 76 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 93 , 94 , 96 , 102 , 106 , 107 , 110 ; including 12 studies with <5 controls but with sufficient numbers of cases to meet our inclusion criteria. 71 , 74 , 75 , 78 , 81 , 84 , 85 , 88 , 89 , 96 , 106 , 107 Another 12 studies used at least 1 midsized control cohort, 68 , ...…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A scoping review of autoantibodies as biomarkers for canine autoimmune disease

Treeful

Coffey

Friedenberg

2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Autoantibody biomarkers are valuable tools used to diagnose and manage autoimmune diseases in dogs. However, prior publications have raised concerns over a lack of standardization and sufficient validation for the use of biomarkers in veterinary medicine. Objectives Systematically compile primary research on autoantibody biomarkers for autoimmune disease in dogs, summarize their methodological features, and evaluate their quality; synthesize data supporting their use into a resource for veterinarians and researchers. Animals Not used. Methods Five indices were searched to identify studies for evaluation: PubMed, CAB Abstracts, Web of Science, Agricola, and SCOPUS. Two independent reviewers (AET and ELC) screened titles and abstracts for exclusion criteria followed by full‐text review of remaining articles. Relevant studies were classified based on study objectives (biomarker, epitope, technique). Data on study characteristics and outcomes were synthesized in independent data tables for each classification. Results Ninety‐two studies qualified for final analysis (n = 49 biomarker, n = 9 epitope, and n = 34 technique studies). A high degree of heterogeneity in study characteristics and outcomes reporting was observed. Opportunities to strengthen future studies could include: (1) routine use of negative controls, (2) power analyses to inform sample sizes, (3) statistical analyses when appropriate, and (4) multiple detection techniques to confirm results. Conclusions These findings provide a resource that will allow veterinary clinicians to efficiently evaluate the evidence supporting the use of autoantibody biomarkers, along with the varied methodological approaches used in their development.

show abstract

References

2018

Breed Predispositions to Disease in Dogs and Cats

View full text Add to dashboard Cite

Antinuclear Antibodies (ANA) in Gordon Setters with Symmetrical Lupoid Onychodystrophy and Black Hair Follicular Dysplasia

Cited by 14 publications

References 11 publications

DLA Class II Alleles Are Associated with Risk for Canine Symmetrical Lupoid Onychodystropy (SLO)

DLA Class II Alleles Are Associated with Risk for Canine Symmetrical Lupoid Onychodystropy (SLO)

A scoping review of autoantibodies as biomarkers for canine autoimmune disease

References

Contact Info

Product

Resources

About